Skip to main content
. 2021 Dec 3;95:153868. doi: 10.1016/j.phymed.2021.153868

Table 1.

Characteristics between the two groups of severe patients.

Total (n = 111) Conventional treatment group (n = 52) Huashibaidu group (n = 59) p
Gender(Female, No., %) 36 (32.4%) 22 (42.3%) 14 (23.7%) 0.037
Age(year, X¯±S) 61.81 (12.71) 61.29 (12.60) 62.27 (12.89) 0.686
Symptoms(No., %)
Fever 31 (27.9%) 13 (25.0%) 18(30.5%) 0.519
Cough 66 (60.0%) 27 (51.9%) 39 (67.2%) 0.102
Tachypnea 38 (34.2%) 12 (23.1%) 26 (44.1%) 0.020
Coma 1 (0.9%) 0 (0.0%) 1 (1.7%) >0.999
Sore throat 1 (0.9%) 1 (1.9%) 0 (0.0%) 0.473
Diarrhea 2 (1.8%) 0 (0.0%) 2 (3.4%) 0.497
Nausea and vomiting 1 (0.9%) 0 (0.0%) 1 (1.7%) >0.999
Comorbidity (No., %)
Cardiovascular diseases 49 (44.1%) 25 (48.1%) 24 (40.7%) 0.433
Digestive system disease 14 (12.6%) 6 (11.5%) 8 (13.6%) 0.749
Endocrine system disease 19 (17.1%) 8 (15.4%) 11 (18.6%) 0.649
Malignant tumor 6 (5.4%) 2 (3.8%) 4(6.8%) 0.683
Nervous system disease 2 (1.8%) 0 (0.0%) 2 (3.4%) 0.497
Respiratory system disease 8 (7.2%) 2 (3.8%) 6 (10.2%) 0.279
Vital signs
Body temperature (°C, X¯±S) 36.90 (0.70) 36.95 (0.79) 36.86 (0.61) 0.669
Heart rate (beats/min, X¯±S) 90.91 (11.96) 89.85 (12.06) 91.85 (11.89) 0.382
Respiratory rate (breaths/min, IQR) 22.00 (20.50, 23.00) 22.00 (20.50, 23.00) 22.00 (22.00, 22.50) 0.126
Systolic blood pressure (mmHg, X¯±S) 130.59 (16.59) 126.44 (19.02) 135.88 (14.06) 0.022
Diastolic blood pressure (mmHg, X¯±S) 81.86 (10.38) 78.75 (9.83) 85.24 (10.18) 0.008
Laboratory results
White blood cell count (10−9/l, IQR) 6.43 (5.04, 9.00) 6.56 (5.00, 8.88) 6.42 (5.04, 9.03) 0.951
Neutrophil cell count (10−9/l, IQR) 5.08 (3.56, 7.49) 5.10 (3.53, 7.50) 4.89 (3.57, 7.40) 0.939
Lymphocyte count (10−9/l, IQR) 0.90 (0.60, 1.29) 0.92 (0.65, 1.09) 0.84 (0.60, 1.33) 0.866
Immature granulocyte count (10−9/l, IQR) 0.03 (0.01, 0.12) 0.03 (0.01, 0.12) 0.03 (0.01, 0.09) 0.929
monocytes count (10−9/l, IQR) 0.41 (0.26, 0.53) 0.40 (0.30, 0.50) 0.41 (0.26, 0.57) 0.880
Eosinophils count (10−9/l, IQR) 0.02 (0.00, 0.08) 0.01 (0.00, 0.06) 0.04 (0.01, 0.08) 0.141
Hemoglobin (g/l, X¯±S) 123.19 (17.39) 121.12 (16.64) 125.02 (17.97) 0.238
Platelet count (10−9/l, IQR) 217.00 (161.50, 280.00) 221.50 (154.75, 290.50) 215.00 (168.50, 271.00) 0.848
IL-6 (pg/ml, IQR) 8.99 (6.99, 12.80) 8.84 (6.55, 13.65) 9.19 (7.26, 11.90) 0.927
AmyloidA(mg/l, IQR) 179.00 (78.80, 245.64) 186.92 (146.75, 253.92) 172.10 (45.95, 225.10) 0.123
α- Rockulosidase (U/l, IQR) 22.00 (20.00,28.00) 22.00 (19.25, 26.00) 23.00 (20.00, 29.00) 0.298
Albumin (g/l, X¯±S) 30.43 (3.78) 29.64 (3.61) 31.10 (3.82) 0.042
Prealbumin (mg/l, IQR) 131.00 (84.00, 192.00) 120.00 (85.25, 163.50) 137.00 (81.00, 221.00) 0.335
Aminotransferase alanine (U/l, IQR) 38.50 (22.50, 54.50) 41.00 (24.00, 54.00) 38.00 (21.00, 58.00) 0.721
Aminotransferase aspartate (U/l, IQR) 37.00 (29.00, 56.00) 39.00 (30.50, 55.00) 34.00 (26.00, 56.00) 0.591
Total bilirubin (μmol/l, IQR) 11.95 (9.15, 15.90) 11.10 (8.75, 13.75) 12.90 (9.80, 16.75) 0.178
Indirect bilirubin (μmol/l, IQR) 7.70 (5.62, 10.55) 7.50 (5.95, 9.25) 8.10 (5.05, 11.50) 0.708
Direct bilirubin (μmol/l, IQR) 4.10 (3.20, 5.40) 3.90 (3.00, 4.65) 4.45 (3.32, 5.88) 0.072
Lactate dehydrogenase (U/l, IQR l) 339.00 (261.00, 451.00) 350.00 (275.75, 447.25) 304.00 (254.00, 449.00) 0.371
Uric acid ((μmol/l, IQR) 225.00 (182.25, 299.50) 207.00 (168.50, 282.50) 233.00 (189.50, 335.50) 0.148
Creatinine (μmol/l, IQR) 70.50 (59.20, 83.57) 70.90 (56.85, 81.35) 70.10 (60.40, 90.80) 0.474
Blood urea nitrogen (mmol/l, IQR) 4.85 (3.92, 6.57) 5.00 (3.65, 6.65) 4.70 (4.20, 5.75) 0.895
D-dimer (μg/ml, IQR) 1.10 (0.56, 3.44) 1.08 (0.55, 1.95) 1.46 (0.64, 7.91) 0.118
Prothrombin time activity (%, IQR) 96.20 (78.30, 118.30) 96.20 (81.40, 116.50) 93.50 (76.75, 120.80) 0.511
Baseline oxygen saturation status (No., %)
1 90 45 45 0.575
2 1(1.1%) 1(2.2%) 0(0%)
3 3(3.3%) 2(4.4%) 1(2.2%)
4 8(8.9%) 38(84.4%) 40(88.9%)
4(8.9) 4(8.9%)
Medication (No., %)
Antivirals 63(57.3%) 40 (78.4%) 23 (39.0%) <0.001
Antibiotics 79 (71.8%) 46(90.2%) 33 (55.9%) <0.001
Immune intervention IFN-γ 45 (17.1%) 18 (35.3%) 27 (45.8%) 0.318
Hormone usage 33 (30.0%) 18 (35.3%) 15 (25.4%) 0.365

Notes:P values were calculated by Pearson's chiquared test or fisher's exact test for Count Data, and t-test or Mann-Whitney test, as appropriate. P values denoted the comparison among Conventional treatment group and Huashibaidu group.